美股A股
StockGist
Back
10-Q2026-05-06· deepseek-chat

ONC · BeOne Medicines Ltd.

0001628280-26-030867

SEC filing

Summary

Exceptional quarter driven by BRUKINSA-led revenue acceleration and operating leverage, with net income surging from near break-even to $227M.

Key takeaways

Full analysis

BRUKINSA-Led Revenue Acceleration

Margin Expansion Through Mix and Efficiency

Operating Leverage and Profitability Inflection

Cash Flow Transformation

Net cash provided by operating activities increased to $201.3 million from $44.1 million in the prior-year period, driven by higher net income and working capital improvements. Capital expenditures decreased to $40.8 million from $56.4 million, resulting in free cash flow of $160.5 million compared to negative free cash flow in the prior-year period.

Outlook and Risks

As we continue to expand our business, the amount and duration of our credit exposure will be expected to increase, as will the breadth of the entities to which we have credit exposure. These statements involve risks and uncertainties, including those described in Part II—Item 1A—Risk Factors of this Quarterly Report, that may cause actual future events or results to differ materially from those expected.